BIOTECHNOLOGY
ovid-19 is caused by the beta coronavirus SARS-CoV-2, one of seven coronavirus species known to infect humans. Based on phylogenetic analyses, SARS-CoV-2 was shown to share remarkably high sequence similarity with SARS-CoV-1, suggesting that antibodies and compounds previously screened for use against SARS-CoV-1 could be lead candidates in the development of therapeutics against Covid-19. A rapid immune response assessment and quantifi cation of potentially cross-reactive antibodies against SARS-CoV-2 will, therefore, be crucial in selecting the best therapeutic candidates. SARS-CoV-2 is a single-stranded RNA-enveloped virus, and its genome encodes for several structural and functional proteins including the spike protein that covers the surface of the virus. T e spike protein consists of two distinct functional subunits, S1 and S2, that mediate receptor recognition, cell attachment and fusion during infection. In the case of SARS-CoV-1 and SARS-CoV-2, homology modelling of the respective spike proteins revealed a sequence similarity of 75-80%,
C
accounting for the fact that SARS-CoV-1 and SARS-CoV-2 share the same entry mechanisms into the host cells. Both bind to the angiotensin-converting enzyme (ACE2), a receptor that is highly expressed on the surface of human respiratory epithelial cells.
Based on the high degree of similarity
between SARS-CoV-1 and SARS-CoV-2, it was therefore speculated that cross- reactive epitopes could exist, which could be exploited to rapidly repurpose existing therapeutic approaches or develop new vaccines. During the initial SARS outbreak in 2002, several monoclonal antibodies including CR3022 were developed against the SARS-CoV-1 spike protein with the goal to inhibit entry into the human host cell. Although the CR3022 antibody failed to neutralise SARS-CoV-2, it was shown to cross-react with a conserved epitope on SARS-CoV-2 RBD. Moreover, used in combination with another antibody, CR3014, neutralisation was achieved due to synergistic binding of diff erent epitopes on the RBD. Such a combined antibody therapy was therefore suggested as an option in the treatment of Covid-19 patients.
36
www.scientistlive.com
Viola Denninger on assessing cross-reactivity of antibodies against SARS-CoV-1 and SARS-CoV-2 microfl uidic antibody-affi nity profi ling
To understand the underlying mechanisms that govern the functional immune response to SARS-CoV-2 scientists have used microfl uidic antibody- affi nity profi ling (MAAP) to assess and quantify the cross-reactivity between CR3022 and the spike S1 proteins of SARS-CoV-1 and SARS-CoV-2, as well as the cross-reactivity of the two respective spike S1 proteins and a Covid-patient derived neutralising anti-SARS-CoV-2 monoclonal antibody. T eir results indicate a unidirectional cross-reactivity with only CR3022 readily recognising the spike S1 subunits of both viruses. Importantly, the team behind the research could not detect any binding of the anti-SARS-CoV-2 antibody to the S1 subunit of SARS-CoV-1, emphasising the selectivity for the newly evolved virus.
ANTIBODIES ASSESSING By using MAAP on the Fluidity
One-W Serum to determine the affi nities of CR3022 and AS35 against the spike S1 subunits of SARS-CoV-1 and SARS-CoV-2, the scientists can evaluate cross-reactivity of an antibody to various antigens even in a complex background such as serum. T is approach can be used to quantify the immune response of cross-reactive antibodies in patients or vaccinated individuals, as well as to rapidly evaluate therapeutic antibodies against the emerging mutant variants of SARS-CoV-2.
Viola Denninger is with Fluidic Analytics.
www.fluidic.com
The Fluidity One-W system
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
